Skip to main content

Table 1 Gene expression profiles of prostate cancer used for integrative analysis#

From: Integrative analysis reveals disease-associated genes and biomarkers for prostate cancer progression

No. Exp. Platform No. Probes Samples Series No. Samples of prostate cancer stages References
     NAP BN PCA MET  
     (I) (II) (III) (IV)  
     Early phase Middle phase Late phase  
Exp-1 Affymetrix HG-U133P2 GPL570 54,675 GSE3325 0 6 7 6 [76]
Exp-2 cDNAChinnaiyan Human 20K Hs6 GPL2013 20,000 GES6099 0 15 32 20 [77]
Exp-3 Agilent-014850 4x44K G4112F GPL4133 45,220 GSE27616 0 2 5 4 [78]
Exp-4 Affymetrix HG-U133A GPL96 22,283 GSE3868 2 0 22 0 [79]
Exp-5 Affymetrix HGU95A - 12,626 - 9 0 25 0 [80]
Exp-6 Affymetrix HG-U133P2 GPL570 54,675 GSE17951 0 45 109 0 [81, 82]
Exp-7 Agilent-014850 4x44K G4112F GPL6480   GSE28204 0 4 4 0 [83]
Exp-8 Affymetrix HG_U95Av2 GPL8300 12,625 GSE6919 18 0 65 25 [84, 85]
  1. #Abbreviations: NAP: normal prostate samples, BN: benign samples, PCA: primary prostate cancer samples, MET: metastatic prostate cancer samples